Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Pawtucket, Rhode Island Clinical Trials

A listing of Pawtucket, Rhode Island clinical trials actively recruiting patient volunteers.

RESULTS

Found (7) clinical trials

Brief Intervention to Reduce Drinking and Intimate Partner Violence in Women

The purpose of this study is to examine whether adding a brief alcohol treatment to standard violence intervention programs for women will result in reduced drinking, reduced partner violence perpetration, and reduced partner violence victimization. We hypothesize that, relative to standard care, women receiving the additional brief alcohol intervention will …

Phase

2.3 miles

Learn More »

Radiation Therapy Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva

PRIMARY OBJECTIVES: I. To determine the efficacy of cisplatin, gemcitabine (gemcitabine hydrochloride), and intensity-modulated radiation therapy (IMRT) in achieving a complete pathologic response when used for the primary treatment of locally-advanced squamous cell carcinoma of the vulva. SECONDARY OBJECTIVES: I. To determine the efficacy of cisplatin, gemcitabine, and IMRT in …

Phase

3.57 miles

Learn More »

The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational treatment to learn whether it is appropriate for treating a specific disease. The purpose of this study is to determine whether certain patients between the ages of 50 and …

Phase

4.0 miles

Learn More »

Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer

This is an open-label, single-arm Phase 2 study to evaluate the efficacy and safety of combination of niraparib and dostarlimab (TSR-042) in participants with advanced, relapsed, high-grade ovarian, fallopian tube, endometrioid, clear cell ovarian or primary peritoneal cancer without known breast cancer susceptibility gene (BRCA) mutation who have platinum-resistant disease …

Phase

5.88 miles

Learn More »

Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

This is a randomized, blinded, non-comparative, two-arm Phase 2 clinical trial to assess the efficacy and safety of AGEN2034 administered with placebo (Treatment Arm 1 - monotherapy) or with AGEN1884 (Treatment Arm 2 - combination therapy) for treatment of patients with advanced cervical cancer who relapsed or progressed after receiving …

Phase

5.88 miles

Learn More »

Testing the Addition of an Immunotherapy Drug Tremelimumab to the PARP Inhibition Drug Olaparib for Recurrent Ovarian Fallopian Tube or Peritoneal Cancer

PRIMARY OBJECTIVES: I. To determine whether olaparib plus tremelimumab has adequate safety in the study population. (Safety Lead-in Trial Components) II. To compare the progression-free survival (PFS) duration of olaparib monotherapy versus olaparib plus tremelimumab in women with recurrent, platinum sensitive ovarian, primary peritoneal, or fallopian tube cancer. (Phase II …

Phase

5.88 miles

Learn More »

Ribociclib and Letrozole Treatment in Ovarian Cancer

Ribociclib (formerly LEE011) is an orally bioavailable, highly selective small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). Ribociclib has been approved by the United States Food and Drug Administration (U.S. FDA) and the European Commission as an initial endocrine-based therapy for the treatment of postmenopausal women with hormone …

Phase

5.88 miles

Learn More »